Previous 10 | Next 10 |
Protagonist Therapeutics (NASDAQ:PTGX) has selected PN-235 (JNJ-77242113) as the final candidate to advance into phase 2 under collaboration with Johnson & Johnson (NYSE:JNJ) division Janssen Biotech. The oral interleukin-23 (IL-23) antagonist will be investigated in phase 2 studies for p...
Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications PN-235 (JNJ-77242113) now expected to advance into multiple Phase 2 clinical studies in 2022, for indications including psoriasis and inflam...
Rusfertide, a drug in development from Protagonist Therapeutics (NASDAQ:PTGX) for hereditary hemochromatosis, achieved its primary endpoint in a phase 2a trial. That endpoint found that patients on rusferrtide had 0.009 phlebotomies per month during the study compared to 0.28 phlebotomies per...
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis Rusfertide demonstrated favorable safety, tolerability, and therapeutic effect, decreasing and normalizing average TSAT ...
Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences PR Newswire NEWARK, Calif. , Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V....
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting Two oral presentations highlighting updated results of PV patients on rusfertide achieving hematocrit control whil...
Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Resumption of the Phase 2 study of rusfertide in polycythemia vera now underway, following swift removal of the FDA clinical hold Positive proof-of-concept data for rusfertide...
Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen PR Newswire NEWARK, Calif. , Oct. 26, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, short squeeze stocks are once again in focus for investors. Source: Shutterstock Indeed, the meme-stock party we’ve seen take full flight at the beginning of the year has waned to some degree. Howev...
While the S&P 500 index added ~1.8% gain over the week, its healthcare constituents underperformed with a ~0.8% rise yet, recording their first weekly gain in more than a month. Dragged down by pharma stocks, the sector became the second-worst performer in the index for ano...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...